{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:16:51Z","timestamp":1793690211536,"version":"4.5.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study retrospectively investigated the influence of urodynamic parameters and patient characteristics on success rates among patients with overactive bladder (OAB) and urodynamic detrusor overactivity (DO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Consecutive patients with OAB and urodynamic DO initially received solifenacin, mirabegron, or combination of both for 1\u20133 months. If failed, patients were switched to another OAB medication subtype or provided additional OAB medication for a total of 6 months. A successful treatment was defined as an improvement in urgency severity and a global response assessment of \u22651. Success rates after initial or modulated OAB medication were analyzed based on patient and urodynamic characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 453 patients were enrolled, among whom 144, 255, and 54 received solifenacin, mirabegron, and combined medications, respectively. Among the patients, 259 (57.2%) had OAB dry and 194 (42.8%) had OAB wet. Patients receiving mirabegron alone had a significantly higher initial medication success rate compared to that of others. Patients with a phasic DO (50.7%), bladder outlet obstruction (BOO, 52.5%), and no central nervous system (CNS) lesions (47.5%) exhibited higher success rates than those with a terminal DO (42.0%), no BOO (42.7%), and CNS lesions (31.6%), respectively. After switching or modulating the initial OAB medication following treatment failure, 115 (62.2%) of 185 patients still showed improvement in OAB symptoms, with an overall success rate of 70.2% after 6 months of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Initial solifenacin or mirabegron treatment had a success rate of around 50%. In general, patients with a phasic DO, urodynamic BOO, and no CNS lesions have higher success rates than those with a terminal DO, no BOO, and CNS lesions, respectively. Success rates can further be improved by switching or modulating OAB medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_264_20","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T22:54:35Z","timestamp":1612652075000},"page":"441-447","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice"],"prefix":"10.4103","volume":"34","author":[{"given":"Hsiu-Jen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20240828","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardization of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"R2-14-20240828","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"R3-14-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the united states","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"R4-14-20240828","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"R5-14-20240828","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1464-410X.2003.04682.x","article-title":"Prevalence of overactive bladder in Asian men: An epidemiological survey","volume":"93","author":"Moorthy","year":"2004","journal-title":"BJU Int"},{"key":"R6-14-20240828","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"R8-14-20240828","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.urology.2011.10.020","article-title":"High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms","volume":"79","author":"Chiu","year":"2012","journal-title":"Urology"},{"key":"R9-14-20240828","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/nau.21057","article-title":"Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome","volume":"30","author":"Chung","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R10-14-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/luts.12103","article-title":"Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder","volume":"9","author":"Wang","year":"2017","journal-title":"Low Urin Tract Symptoms"},{"key":"R11-14-20240828","doi-asserted-by":"crossref","first-page":"e4962","DOI":"10.1097\/MD.0000000000004962","article-title":"High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment","volume":"95","author":"Liao","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"R12-14-20240828","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY)","volume":"35","author":"Abrams","year":"2017","journal-title":"World J Urol"},{"key":"R13-14-20240828","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/nau.23170","article-title":"Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)","volume":"36","author":"Apostolidis","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"R14-14-20240828","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urology.2007.03.063","article-title":"Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms","volume":"70","author":"Kuo","year":"2007","journal-title":"Urology"},{"key":"R15-14-20240828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","article-title":"Muscarinic receptor antagonists in the treatment of overactive bladder","volume":"55","author":"Chapple","year":"2000","journal-title":"Urology"},{"key":"R16-14-20240828","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int J Clin Pract"},{"key":"R17-14-20240828","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"R18-14-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00210-012-0824-1","article-title":"Pharmacological profile of \u03b23-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome","volume":"386","author":"Igawa","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R19-14-20240828","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: A prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"key":"R20-14-20240828","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/iju.13498","article-title":"Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms\/overactive bladder: Comparison with placebo and tolterodine","volume":"25","author":"Sebastianelli","year":"2018","journal-title":"Int J Urol"},{"key":"R21-14-20240828","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"R22-14-20240828","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"R23-14-20240828","first-page":"O53","article-title":"Therapeutic efficacy of low dose (25 mg) mirabegron therapy for the patients with mild to moderate overactive bladder symptoms due to central nervous system diseases","volume":"11","author":"Chen","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"R24-14-20240828","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","article-title":"Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients","volume":"53","author":"Kay","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"R25-14-20240828","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/ggi.13465","article-title":"Safety and therapeutic efficacy of mirabegron in very old patients with overactive bladder and multiple comorbidities","volume":"18","author":"Lee","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"R26-14-20240828","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/UROS.UROS_2_18","article-title":"Comparative persistence, switch rates, and predictors for discontinuation of antimuscarinics for overactive bladder: A 10-year nationwide population-based study in Taiwan","volume":"29","author":"Chen","year":"2018","journal-title":"Urol Sci"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_264_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:39:13Z","timestamp":1787845153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_264_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_264_20","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}